Important note: Information in this article was accurate in March, 2002. The state of the art may have changed since the publication date.
 |
Project Inform Perspectives 34 - March, 2002
Starting November 27, 2001 at 3pm EST, a study allowing for access to the fusion inhibitor T-20 (Pentafuside) began. However, because there's a severe supply problem, this study was very limited and only provided drug to 168 people in the United States. All slots were filled within weeks. The study may be expanded later in 200, perhaps by summer. Interested physicians should call 1-888-722-6321 for more information.
The study is limited to individuals who need T-20 to put together a viable anti-HIV regimen, must have a viral load over 10,000 copies and have a CD4+ cell count below 50. Physicians are encouraged to give first preference to people who have had an AIDS-defining opportunistic infection within the last 90 days and have a CD4+ cell count below 50 while taking potent anti-HIV therapy. Secondary preference is encouraged for people with CD4+ cell counts below 50 for the last 90 days despite taking potent therapy. While the deadline has passed and the program full/closed to enrollment, as more drug becomes available the program might expand/increase in size. If or when the program expands and accepts new enrollees, the Project Inform hotline will have more information. Visit the website frequently or call the hotline for updates!
020301
PI020302
©2002. This document is copyrighted by Project Inform, 205 13th Street, #2001, San Francisco, CA 94103. Treatment Hotline: 800-822-7422 (toll-free) or 415-558-9051 (in the San Francisco Bay Area and internationally) All Project Inform materials may be reprinted and/or distributed without prior permission. However, reprints may not be edited and must include the following text: "From Project Inform, for more information contact the Project Inform National HIV/AIDS Treatment Hotline, 800-822-7422." For permission to edit any Project Inform material for further publication, contact David Evans at the Project Inform office.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1985, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS , or the party credited as the provider of the content.